|
SmithOnStocks publishes reports on biotechnology, medical technology and pharmaceutical companies. Content in Company Reports and the Blog is free. The Company Reports section appears in the header and can be accessed by clicking on it. The Site Navigation component of the About Us section gives detailed instructions on how to use this website. I also offer a subscription service that provides a newsletter, investment insights and detailed financial models on certain companies at a price of $50.00 per year. Premium subscription services that provide direct access to the author are available at prices that are dependent upon the service provided. A.P. Pharma Receives Complete Response Letter on APF530 (APPA.OB, $0.34) A.P. Pharma has just released the disappointing news that it has received a Complete Response Letter for APF530. The press release described... Investment Implications of the Acquisition of MAP Pharmaceuticals by Allergan Allergan to Acquire MAP Pharmaceuticals Allergan (AGN) has announced that it will acquire MAP Pharmaceuticals (MAPP) at a price of $25 per share... Cadence: Management Guides to a Near Doubling of Ofirmev Sales in 2013 My confidence in my long standing Buy recommendation on Cadence (CADX) has been strengthened by its pre-announcement that 4Q, 2012 sales of Ofirmev... InSite Vision: Upcoming Results on the DOUBle Trial May Not Be as Binary as I Have Been Thinking I met with the CEO, Tim Ruane, and CFO, Lou Drapeau, of InSite Vision (INSV.OB) in early January during my trip to the JP Morgan conference in... Trius: Why Last Friday’s Equity Offering is good for the Stock (TSRX, $4.90) Investment Opinion Trius (TSRX) completed an equity offering on Friday January 19 in which it sold 6.3 million shares at $4.465. I assume that the... Discovery Laboratories Announces Changing of the Guard (DSCO, $2.21) New Board and New CEO There has been a significant leadership change at Discovery Laboratories (DSCO) which has appointed a new CEO. In addition,... |
